{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:14:47Z","timestamp":1794395687128,"version":"4.9.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamacardio.2021.4027","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:16:08Z","timestamp":1634512568000},"page":"26","source":"Crossref","is-referenced-by-count":108,"title":["Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure"],"prefix":"10.1001","volume":"7","author":[{"given":"G. Michael","family":"Felker","sequence":"first","affiliation":[{"name":"Division of Cardiology, Duke University School of Medicine, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[{"name":"Instituto Cardiovascular de Rosario, Estudios Cl\u00ednicos Latino Am\u00e9rica, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Centre, British Heart Foundation, Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Anand","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa G.","family":"Crespo-Leiro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Universidad da Coru\u00f1a, A Coru\u00f1a, Galicia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Goncalvesova","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odd. Srdcovehozlyhavania a Transplantacie, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Howlett","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Heart Transplant Unit, St. Vincent\u2019s Hospital Sydney, Darlinghurst, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Parkhomenko","sequence":"additional","affiliation":[{"name":"Emergency Cardiology Department, Ukranian Strazhesko Institute of Cardiology, Kiev, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Tomcs\u00e1nyi","sequence":"additional","affiliation":[{"name":"Cardiology Department, St. John of God Hospital, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddique A.","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Heitner","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hucko","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady I.","family":"Malik","sequence":"additional","affiliation":[{"name":"Research and Development, Cytokinetics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Francisco VA Medical Center, San Francisco, California"},{"name":"Division of Cardiology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"hoi210068r1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.cardfail.2015.04.013","article-title":"Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.","volume":"21","author":"Fang","year":"2015","journal-title":"J Card Fail"},{"issue":"11","key":"hoi210068r2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejhf.2018.20.issue-11","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"hoi210068r3","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines.","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"hoi210068r4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure.","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"issue":"6-7","key":"hoi210068r5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejheart.2007.04.003","article-title":"Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.","volume":"9","author":"Metra","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"hoi210068r6","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1161\/CIR.0b013e31824f2173","article-title":"Decision making in advanced heart failure: a scientific statement from the American Heart Association.","volume":"125","author":"Allen","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"hoi210068r7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/CIRCHEARTFAILURE.113.000761","article-title":"Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With the Guidelines.","volume":"7","author":"Allen","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"9","key":"hoi210068r8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jchf.2018.03.019","article-title":"Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis.","volume":"6","author":"Nizamic","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"9792","key":"hoi210068r9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","article-title":"Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.","volume":"378","author":"Teerlink","year":"2011","journal-title":"Lancet"},{"issue":"9792","key":"hoi210068r10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"issue":"10062","key":"hoi210068r11","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"key":"hoi210068r12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure.","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi210068r13","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/ejhf.v22.11","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hoi210068r14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF.","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"3","key":"hoi210068r15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/archinternmed.2010.371","article-title":"Resource use in the last 6 months of life among Medicare beneficiaries with heart failure, 2000-2007.","volume":"171","author":"Unroe","year":"2011","journal-title":"Arch Intern Med"},{"issue":"11","key":"hoi210068r16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003032","article-title":"INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profiling identifies ambulatory patients at high risk on medical therapy after hospitalizations for heart failure.","volume":"9","author":"Stewart","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"10","key":"hoi210068r17","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jama.294.10.1240","article-title":"Risk-treatment mismatch in the pharmacotherapy of heart failure.","volume":"294","author":"Lee","year":"2005","journal-title":"JAMA"},{"key":"hoi210068r18","author":"Teerlink"},{"issue":"12","key":"hoi210068r19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community.","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"issue":"10","key":"hoi210068r20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jchf.2020.05.005","article-title":"Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial.","volume":"8","author":"Mann","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"21","key":"hoi210068r21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"10","key":"hoi210068r22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"24","key":"hoi210068r23","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/eurheartj\/ehp338","article-title":"Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.","volume":"30","author":"Metra","year":"2009","journal-title":"Eur Heart J"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2785151\/jamacardiology_felker_2021_oi_210068_1640293637.09877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T11:06:59Z","timestamp":1641985619000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2785151"}},"subtitle":["A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2021.4027","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}